Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease.
The DOI matches its OpenAlex record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Temporal cortical sections from postmortem brains of individuals without any dementing condition and with different degrees of severity of Alzheimer's disease (AD) evaluated by the Clinical Dementia Rating scale (CDR 0-CDR 3) were analyzed using immunohistochemical procedures. To demonstrate the amyloid-beta-peptide (Abeta) deposition and the neurofibrillary pathology, two monoclonal antibodies were used, a human CERAD Abeta (10D5) antibody raised against the N-terminal region of the Abeta-peptide, and an antibody raised against paired helical filaments (PHF-1). The neuron cell bodies and the glial cells were also recognized by two polyclonal antibodies raised, respectively, against the protein gene peptide (PGP 9.5) and glial fibrillary acidic protein (GFAP). Directly related to severity of AD, progressive deposits of Abeta-peptide were found within cortical pyramidal-like neurons and forming senile plaques. Ultrastructurally, Abeta-peptide deposits were related to neuronal intracytoplasmic organelles, such as the ER, the mitochondria, the Nissl bodies and lipofuscin. We have also found that the intracellular deposition of the Abeta peptide is a neuropathological finding prior to the appearance of PHF-immunoreactive structures. We suggest that the intracellular Abeta deposition in cortical pyramidal neurons is a first neurodegenerative event in AD development and that it is involved in cell dysfunction, neuronal death, and plaque formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
Yan, S. D., Chen, X., Schmidt, A. M., Brett, J., Godman, G., Zou, Y. S., Scott, C. W., Caputo, C., Frappier, T., & Smith, M. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7787 · Cited by 565
Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., & Bayer, T. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01876-6 · Cited by 336
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323
Wertkin, A. M., Turner, R. S., Pleasure, S. J., Golde, T. E., Younkin, S. G., Trojanowski, J. Q., & Lee, V. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9513 · Cited by 231
Turner, R. S., Suzuki, N., Chyung, A. S. C., Younkin, S. G., & Lee, V. M.-Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8966 · Cited by 161
Cited by
ER stress and the unfolded protein response in neurodegeneration
Hetz, C., & Saxena, S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.99 · Cited by 1,013
Du, H., Guo, L., Fang, F., Chen, D., A Sosunov, A., M McKhann, G., Yan, Y., Wang, C., Zhang, H., Molkentin, J. D., et al. (2008) · Nature Medicine · doi:10.1038/nm.1868 · Cited by 932
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
“However, analyses show mitochondria from AD subject autopsy brains do appear to contain A [33, 35, 38, 39].”
BackgroundSultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478
“TheoligomericformofAbspeciesinterferesinmole- cularandbiochemicalalterationsinADmoresothantheextracellular ,insolubleamyloiddeposits[156] [157] [158],suggestingthat Ab-inducedmitochondrialdysfunctioncanplayamajorrolein ADprogressionandpathogenesis[159] [160] [161].”
Hauptmann, S., Scherping, I., Dröse, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., & Müller, W. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.005 · Cited by 469
Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396
“Many other studies of patients with AD (Gouras et al., 2000; Fernández-Vizarra et al., 2004) and Down syndrome (Mori et al., 2002) and of APP-Tg mice (Casas et al., 2004; Lord et al., 2006; Oakley et al., 2006) have demonstrated that intraneuronal accumulation of A is an early pathological change…”
BackgroundWirths, O., Multhaup, G., & Bayer, T. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02737.x · Cited by 350
Amyloid‐Beta Interaction with Mitochondria
Pagani, L., & Eckert, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/925050 · Cited by 309
PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease
Du, F., Yu, Q., Yan, S., Hu, G., Lue, L.-F., Walker, D. G., Wu, L., Yan, S. F., Tieu, K., & Yan, S. S. (2017) · Brain · doi:10.1093/brain/awx258 · Cited by 306
Umeda, T., Tomiyama, T., Sakama, N., Tanaka, S., Lambert, M. P., Klein, W. L., & Mori, H. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22640 · Cited by 266
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268
Bayer (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00008 · Cited by 252
Rhein, V., Baysang, G., Rao, S., Meier, F., Bonert, A., Müller-Spahn, F., & Eckert, A. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9398-y · Cited by 198
“Recently, the focus on toxic species of Ab has switched from its extracellular and fibrillar forms to its soluble species, e.g., oligomers, that can be detected intracellularly and may represent the primary toxic Ab correlate (Fernandez-Vizarra et al. 2004; Lustbader et al. 2004).”
BackgroundEckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177
“Taken together, these fi ndings are in line with the recently proposed hypothesis of an intracellular Aβ toxicity cascade, which suggests that the toxic Aβ species that cause molecular and biochemical abnormalities are in fact intracellular oligomeric aggregates rather than the extracellular, insoluble plaques [6,20].”
BackgroundIntraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody
Youmans, K. L., Tai, L. M., Kanekiyo, T., Stine Jr, W. B., Michon, S.-C., Nwabuisi-Heath, E., Manelli, A. M., Fu, Y., Riordan, S., Eimer, W. A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-8 · Cited by 164
“remains following neuronal apoptosis [7-9,51].”
BackgroundInfluentialChristensen, D. Z., Kraus, S. L., Flohr, A., Cotel, M.-C., Wirths, O., & Bayer, T. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0451-6 · Cited by 126
“reported in AD [6, 9, 11], as well as in Down syndrome”
BackgroundNishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M. P., Klein, W. L., & Mori, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080480 · Cited by 127
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114
Ultrastructural Localization of Intraneuronal Aβ-Peptide in Alzheimer Disease Brains
Gómez-Ramos, P., & Asunción Morán, M. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11109 · Cited by 76
“Antibodies against Aβ stain not only senile plaques and congophilic angiopathy but also neurons and glial cells in brains of both Alzheimer’s disease (AD) patients and non-demented controls [2,3,7,8,10,11,23,30,31].”
Rhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56
Christensen, D. Z., Bayer, T. A., & Wirths, O. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.014 · Cited by 47
Zhao, X.-S., Wu, Q., Peng, J., Pan, L.-H., Ren, Z., Liu, H.-T., Jiang, Z.-S., Wang, G.-X., Tang, Z.-H., & Liu, L.-S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6055 · Cited by 46
Suelves, N., Saleki, S., Ibrahim, T., Palomares, D., Moonen, S., Koper, M. J., Vrancx, C., Vadukul, D. M., Papadopoulos, N., Viceconte, N., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01578-x · Cited by 43
Mechanisms of Neuron Loss in Alzheimer’s Disease
Mukhin, V. N., Pavlov, K. I., & Klimenko, V. M. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0427-x · Cited by 27
Metadata
- Authors
- Fernández‐Vizarra, P., Fernández, A. P., Castro‐Blanco, S., Serrano, J., Bentura, M. L., Martínez‐Murillo, R., Martínez, A., & Rodrigo, J.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2004-07-01
- Volume
- 19
- Issue
- 3
- Pages
- 823-44
- OpenAlex
- W2190430429
- Cited by
- 121
- References
- 9
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.